Most people never think about industrial gases. They breathe air， fill balloons， maybe buy a cylinder of helium for a party. But walk into a steel mill， a hospital ICU， or a semiconductor fab， and Linde is there—often invisibly， always indispensably. The company， founded in 1879 by Carl von Linde， didn't just pioneer refrigeration;it turned air separation into a global infrastructure business. Today， Linde supplies oxygen， nitrogen。argon， and dozens of specialty gases to customers in more than 100 countries. That reach isn't accidental. It's the result of a century-long bet on on-site plants and long-term contracts， a model that competitors have struggled to replicate.Gas is a terrible product to ship. Oxygen liquefies at -183°C。and transporting it long distances burns money fast. Linde's answer， refined over decades， is to build production right next to the customer. A major steelmaker in China， for instance， gets its own air separation unit on-site， piping oxygen directly into the furnace. Linde operates the plant;the customer pays for the gas. These “on-site” deals typically run 15 to 20 years. That creates a moat: once a plant is built， switching suppliers means rebuilding infrastructure. I've seen facilities where Linde's control room sits inside the customer's fence line—an arrangement that makes the relationship nearly permanent. This isn't glamorous， but it's sticky.What strikes me is how quietly Linde has consolidated the industry. The 2018 merger with Praxair。followed by the 2024 divestiture of most of its US bulk gas business to Messer， reshaped the competitive landscape. Linde kept the high-margin on-site and healthcare segments while shedding lower-margin merchant gas routes. Regulators forced the sale， but Linde walked away with a leaner portfolio. Meanwhile， its engineering division builds the very plants its competitors use—a subtle advantage. If you need a hydrogen liquefier， Linde will happily sell you one， then compete with you on gas supply. That vertical integration gives it visibility into rivals' capacity plans， though the company downplays the point.
Healthcare is another underappreciated engine. Hospitals need medical oxygen， nitrous oxide， and calibration gases for analyzers. Linde's healthcare arm supplies gases and services to thousands of facilities， from rural clinics to large trauma centers. The COVID-19 pandemic exposed how fragile oxygen supply chains can be—India's surge in 2021 strained production worldwide. Linde ramped up output and airlifted equipment， but the crisis also revealed a hard truth: gas supply is critical infrastructure， not a commodity. That realization has pushed Linde toward more resilient local production and digital monitoring. Sensors on tanks now trigger automatic refills before levels drop， reducing emergency calls. Small operational wins。but they matter when lives depend on a continuous flow.Where does Linde go from here?Hydrogen， for one. The company is building electrolyzers and blue hydrogen plants in Europe and the US， betting that decarbonization will create steady demand. But the economics remain uncertain—green hydrogen costs two to three times more than grey， and customers hesitate. Linde's approach is pragmatic: sign long-term offtake agreements with industrial buyers before breaking ground. That caution is typical. It avoids the hype cycle that has burned other energy investors. My take: Linde won't win headlines， but it will keep winning contracts. The company excels at the unglamorous work of making gases reliable， affordable。
and safe. In an era obsessed with disruption。there's something reassuring—and profitable—about a business that just keeps the air flowing.